Objective:To successfully isolate and identify patient-derived ovarian cancer stem cells(OCSC),and to investigate the expression of monocarboxylate transporter 2(MCT2)in OCSC and its effects on the stem-ness and invasiveness of OCSC.Methods:Primary ovarian cancer cells were obtained,and OCSC models were established through screening and culturing.The screened OCSC were designated as the OCSC group,while the adherent primary cells were employed as control group 1.Two MCT2 inhibition constant Ki-specific inhibitors,namely[α-cyano-4-hydroxycinnamic acid(CHC)and ARC155858],were utilized for intervention,setting up the CHC inhibition group and the ARC155858 inhibition group.The group with only the solvent DMSO added was set respectively as CHC control group 2 and ARC 155858 control group 2.Flow cytometry and qRT-PCR were used for identification of OCSC markers.The expression levels and locations of MCT2 were detected by qRT-PCR and immunofluorescence staining.The effects of MCT2 inhibitors on the stemness and invasiveness of OCSC were verified using sphere formation assays and Matrigel invasion assays.Results:A primary OCSC cell bank consis-ting of 23 clinical models was established.qRT-PCR results showed that the expression level of MCT2 in OCSC group(5.78±3.55 and 122.89±19.90)was significantly higher than that in the control group 1(1.01±0.10 and 1.55±1.45),the difference is statistically significant(P＜0.05).Fluorescent quantitative analysis confirmed that MCT2 expression in OCSC group was higher than that in the control group 1(6.79±0.67 AU vs.2.49±1.78 AU,P=0.030).Treatment with MCT2 inhibitors in OCSC resulted in a significant reduction in sphere formation in the CHC inhibition group(6.00±2.17 spheres/1000 cells)compared to the CHC control group 2(14.62±3.07 spheres/1000 cells),the difference is statistically significant(P＜0.01),and in the ARC155858 inhibition group(11.00±4.42 spheres/1000 cells)compared to the ARC155858 control group 2(23.90±4.72 spheres/1000 cells),the difference is statistically significant(P＜0.01).In Matrigel invasion assays,the invasiveness in the in-hibitor group was significantly lower than in the control group(ARC155858:inhibitor group 10.20±5.98 cells vs.control group 67.20±28.96 cells,P＜0.05).Conclusions:This study observed that MCT2 expression significantly increased in OCSC.Inhibition of MCT2 significantly reduces the stemness and invasiveness of OCSC,providing potential research directions for targeted therapy of ovarian cancer.

Objective:To successfully isolate and identify patient-derived ovarian cancer stem cells(OCSC),and to investigate the expression of monocarboxylate transporter 2(MCT2)in OCSC and its effects on the stem-ness and invasiveness of OCSC.Methods:Primary ovarian cancer cells were obtained,and OCSC models were established through screening and culturing.The screened OCSC were designated as the OCSC group,while the adherent primary cells were employed as control group 1.Two MCT2 inhibition constant Ki-specific inhibitors,namely[α-cyano-4-hydroxycinnamic acid(CHC)and ARC155858],were utilized for intervention,setting up the CHC inhibition group and the ARC155858 inhibition group.The group with only the solvent DMSO added was set respectively as CHC control group 2 and ARC 155858 control group 2.Flow cytometry and qRT-PCR were used for identification of OCSC markers.The expression levels and locations of MCT2 were detected by qRT-PCR and immunofluorescence staining.The effects of MCT2 inhibitors on the stemness and invasiveness of OCSC were verified using sphere formation assays and Matrigel invasion assays.Results:A primary OCSC cell bank consis-ting of 23 clinical models was established.qRT-PCR results showed that the expression level of MCT2 in OCSC group(5.78±3.55 and 122.89±19.90)was significantly higher than that in the control group 1(1.01±0.10 and 1.55±1.45),the difference is statistically significant(P＜0.05).Fluorescent quantitative analysis confirmed that MCT2 expression in OCSC group was higher than that in the control group 1(6.79±0.67 AU vs.2.49±1.78 AU,P=0.030).Treatment with MCT2 inhibitors in OCSC resulted in a significant reduction in sphere formation in the CHC inhibition group(6.00±2.17 spheres/1000 cells)compared to the CHC control group 2(14.62±3.07 spheres/1000 cells),the difference is statistically significant(P＜0.01),and in the ARC155858 inhibition group(11.00±4.42 spheres/1000 cells)compared to the ARC155858 control group 2(23.90±4.72 spheres/1000 cells),the difference is statistically significant(P＜0.01).In Matrigel invasion assays,the invasiveness in the in-hibitor group was significantly lower than in the control group(ARC155858:inhibitor group 10.20±5.98 cells vs.control group 67.20±28.96 cells,P＜0.05).Conclusions:This study observed that MCT2 expression significantly increased in OCSC.Inhibition of MCT2 significantly reduces the stemness and invasiveness of OCSC,providing potential research directions for targeted therapy of ovarian cancer.